Linklaters is recruiting a finance team from A&O Shearman’s New York office, including the latter’s global co-head of ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for ...

The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Hi, it’s Aaron Kirchfeld, Pamela Barbaglia, Dinesh Nair and Swetha Gopinath in London, looking at how Europe's biggest buyout ...

(Goldman, 10/24) Bloomberg: How Sanofi's Sale Of Consumer Pharma Arm Opella Turned Into A Brawl After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision ...